| Old Articles: <Older 6671-6680 Newer> |
|---|
 |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.   |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
September 8, 2010
John Keeling |
Buy or Short These Health-Care Provider Stocks? Here are the top two and bottom two health care provider and service companies based on quality of earnings. |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C. |
The Motley Fool
September 7, 2010
John Keeling |
Buy or Short These Health-Care Technology Stocks? Quality of earnings is what matters. |
The Motley Fool
September 7, 2010
John Keeling |
Buy or Short These Health-Care Equipment Stocks? Quality of earnings matters most. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Cerus Finds New Potential in Chronic Fatigue The company has struggled for years but got some good news in a recent study. |
The Motley Fool
September 3, 2010
Brian Orelli |
Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years |
BusinessWeek
September 2, 2010
Simeon Bennett |
David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS. |
| <Older 6671-6680 Newer> Return to current articles. |
